Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778622 | 1.00 | GLI1 (0.34) | GLI1GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL5781963 | 0.82 | CYP1A2 (0.41) | GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL5781957 | 0.82 | CYP1A2 (0.41) | GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL15782102 | 0.79 | GRM2 (0.38) | GLI1GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL30918647 | 0.79 | GRM2 (0.38) | GLI1GRM2GRM3CYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL23004610 | 0.78 | GRM2 (0.37) | GLI1GRM2GRM3CYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL15776151 | 0.78 | GRM2 (0.37) | GLI1GRM2GRM3CYP1A2ALOX15 | |
| SCHEMBL25922441 | 0.77 | KMT2A (0.39) | CYP1A2ALOX15 | |
| Hydrochloric Acid SCHEMBL9192813 | 0.76 | KMT2A (0.38) | CYP1A2ALOX15 | |
| SCHEMBL19222961 | 0.75 | GLI1 (0.36) | GLI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539747-B1 | N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-20060040937-A1 | N-aroyl cyclic amines as orexin receptor antagonists | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1539747-A1 | N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004026866-A1 | N-AROYL CYCLIC AMINES AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040937-A1 | N-aroyl cyclic amines as orexin receptor antagonists | HCRTR2, HCRTR1, NTSR2 | GLI1 3747/4885GRM2 292/4885GRM3 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.